Wave Life Sciences Ltd (NYSE:WVE) had its price objective reduced by JMP Securities from $52.00 to $40.00 in a research note published on Wednesday morning, Analyst Ratings.Net reports. They currently have a market outperform rating on the stock.
Other large investors recently bought and sold shares of the company. Jennison Associates LLC bought a new stake in Wave Life Sciences during the fourth quarter valued at approximately $5,773,000. Clough Capital Partners L P acquired a new stake in Wave Life Sciences during the fourth quarter valued at about $6,210,000. New Leaf Venture Partners L.L.C. acquired a new stake in Wave Life Sciences during the fourth quarter valued at about $12,507,000. Finally, Redmile Group LLC acquired a new stake in Wave Life Sciences during the fourth quarter valued at about $18,326,000.
Shares of Wave Life Sciences (NYSE:WVE) opened at 16.95 on Wednesday. The firm has a 50-day moving average price of $13.35 and a 200-day moving average price of $14.45. Wave Life Sciences has a 1-year low of $8.95 and a 1-year high of $21.00. The company’s market cap is $365.29 million.
Several other equities analysts also recently weighed in on the company. Zacks Investment Research downgraded Wave Life Sciences from a buy rating to a hold rating in a research report on Thursday, February 18th. Jefferies Group began coverage on Wave Life Sciences in a research report on Monday, December 7th. They issued a buy rating and a $28.00 target price on the stock. SunTrust assumed coverage on Wave Life Sciences in a research report on Monday, December 7th. They issued a buy rating and a $26.00 target price on the stock. Finally, Leerink Swann assumed coverage on Wave Life Sciences in a report on Monday, December 7th. They issued an outperform rating and a $20.00 price target for the company. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company presently has an average rating of Buy and an average price target of $28.50.
Wave Life Sciences Pte. Ltd. is a preclinical biopharmaceutical company. The Company uses synthetic chemistry drug development platform to design, develop and commercialize a pipeline of nucleic acid therapeutic candidates. It develops nucleic acid therapeutics that are capable of targeting diseases in a range of organ systems and tissues.

 

Source: WKRB News and Analysis

Trade-Ideas LLC identified Inogen ( INGN) as a strong on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified Inogen as such a stock due to the following factors:
INGN has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $6.7 million.
INGN has traded 405,331 shares today.
INGN is trading at 18.77 times the normal volume for the stock at this time of day.
INGN is trading at a new high 18.14% above yesterday’s close.

‘Strong on High Relative Volume’ stocks are worth watching because major volume moves tend to indicate underlying activity such as M&A events, material stock news, analyst upgrades, insider buying, buying from ‘superinvestors,’ or that hedge funds and momentum traders are piling into a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize. In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success.

More details on INGN:
Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. INGN has a PE ratio of 76. Currently there are 5 analysts that rate Inogen a buy, no analysts rate it a sell, and none rate it a hold.
The average volume for Inogen has been 169,900 shares per day over the past 30 days. Inogen has a market cap of $673.7 million and is part of the health care sector and health services industry. Shares are down 11.8% year-to-date as of the close of trading on Monday.
EXCLUSIVE OFFER: See inside Jim Cramer’s multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
TheStreetRatings.com Analysis:
TheStreet Quant Ratings rates Inogen as a hold. The company’s strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and increase in net income. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity, premium valuation and a decline in the stock price during the past year.
Highlights from the ratings report include:
INGN’s revenue growth has slightly outpaced the industry average of 30.2%. Since the same quarter one year prior, revenues rose by 38.7%. This growth in revenue appears to have trickled down to the company’s bottom line, improving the earnings per share.
INGN’s debt-to-equity ratio is very low at 0.00 and is currently below that of the industry average, implying that there has been very successful management of debt levels. Along with this, the company maintains a quick ratio of 4.25, which clearly demonstrates the ability to cover short-term cash needs.
INOGEN INC has improved earnings per share by 18.2% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, INOGEN INC reported lower earnings of $0.34 versus $1.22 in the prior year. This year, the market expects an improvement in earnings ($0.45 versus $0.34).
Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. When compared to other companies in the Health Care Equipment & Supplies industry and the overall market, INOGEN INC’s return on equity is below that of both the industry average and the S&P 500.

 

Source: The Street

January 6, 2014 7:57 AM EST Tweet Share E-mail
China Natural Resources, Inc. (Nasdaq: CHNR) is furnishing this information statement in connection with its spin-off (the “Spin-off”) of Feishang Anthracite Resources Limited (“Feishang Anthracite”). CHNR intends to effect the Spin-off by way of a distribution in specie of the entire issued share capital of Feishang Anthracite to the holders of the common shares of CHNR (the “Distribution”). Feishang Anthracite is currently a wholly-owned subsidiary of CHNR. Feishang Anthracite is a producer of anthracite coal based in Guizhou province of the People’s Republic of China (the “PRC”) and is primarily engaged in the acquisition, construction and development of anthracite coal mines and the extraction and sale of anthracite coal. After the completion of the Spin-off, CHNR will no longer hold any shares in Feishang Anthracite. In connection with the Spin-off, the ordinary shares of Feishang Anthracite will be distributed on a pro rata basis to holders of record of the common shares of CHNR on January 13, 2014 (the “Distribution Record Date”). Holders of CHNR common shares (“CHNR Shareholders”) will be entitled to receive five Feishang Anthracite ordinary shares for each CHNR common share held on the Distribution Record Date. CHNR Shareholders will not be required to pay any consideration for the Feishang Anthracite ordinary shares that they will be entitled to receive in the Distribution or to surrender or exchange CHNR common shares in order to be entitled to receive Feishang Anthracite ordinary shares and do not need to take any other action in connection with the Spin-off. No CHNR Shareholder approval of the Spin-off or Distribution is required or sought. CHNR is not asking you for a proxy and you are requested not to send CHNR a proxy. The Spin-off is subject to the conditions described under “The Spin-off” in this information statement. Investors who trade in the Feishang Anthracite ordinary shares prior to receipt of the Feishang Anthracite share certificates do so entirely at their own risk. Currently, there is no trading market for Feishang Anthracite ordinary shares. The Feishang Anthracite ordinary shares are expected to be listed on The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”) under the stock code “1738” on or around January 22, 2014. Admission to listing and trading is subject to the approval of the Listing Committee of the Hong Kong Stock Exchange. The Feishang Anthracite ordinary shares will not be listed on any securities exchange in the United States or quoted on any automated inter-dealer quotation system in the United States. An active trading market for Feishang Anthracite ordinary shares is not expected to develop in the United States.

 

Source: Street Insider

Solazyme, Inc. (Nasdaq: SZYM), now known as TerraVia, has signed a definitive multi-year global supply agreement with Unilever. The five-year agreement provides for Unilever to purchase renewable algae oils for use in personal care products and reflects the culmination of more than seven years of collaboration between Solazyme and Unilever.

This new agreement builds upon Solazyme’s initial supply relationship with Unilever for renewable algae oils, which Unilever began incorporating into its products in 2014. These oils are being produced and delivered to Unilever routinely from the Solazyme Bunge Renewable Oils facility. This new five-year, multi-oil supply agreement includes a broad portfolio of oils for use in its personal care products. Production of these oils will take place at the Solazyme Bunge Renewable Oils facility in Brazil and pricing terms are based upon variable production cost plus a defined contribution margin. Oils purchased under this new supply agreement are expected to represent total revenue of more than $200 million over the term of the agreement.

Jonathan Wolfson, TerraVia’s CEO, commented, “Our mission is to deliver products from algae that are better for people and better for our planet. We are proud to partner with Unilever, a global leader in health and wellbeing, whose products touch over 2 billion people on any given day. The growth of our partnership reflects over seven years of collaboration during which we have demonstrated our ability to develop and deliver unique, high performance, and highly sustainable oils at scale, as we continue our shift to focusing on higher value products.”

Alan Jope, Personal Care President of Unilever said, “The decision to use algae oils is fully aligned with the Unilever Sustainable Living Plan and with our goal to grow the business while reducing our overall environmental footprint. We have been working with Solazyme for many years to develop novel ingredients from algae, which improve the performance and sustainability profile of our personal care products. Solazyme has already been delivering consistent, sustainable and high performing algae oils, and we look forward to this next and greatly expanded commercial phase of the relationship.”

The Solazyme Bunge Renewable Oils facility in Brazil produces more oil per hectare/acre with a lower greenhouse gas footprint than nearly all major commercially available plant oils. The Brazil facility embodies the principles of sustainable production and is co-located with a Bonsucro®-certified sugarcane mill that uses the waste sugarcane material (bagasse) as an efficient, renewable source of energy.

 

Source:  Street Insider

“Alex, I’ll take Biotech Shocking Surprises for $400.”

“This company is the first in 40 years to develop a drug which improves upon the standard of care for elderly patients with high-risk acute myeloid leukemia.”

“Oof, Alex, this is a tough one. Okay, here goes… Who is Celator Pharmaceuticals (CPXX – Get Report) ?”

Brand New – TheStreet’s Biotech Bible! Before you invest one single dime in any biotech stock you have got to KNOW WHAT YOU ARE BUYING! Get THE most comprehensive text covering the 171 biotech companies that have gone public since 2013! There’s nothing else like it for digging into this highly speculative group of stocks. Get a FREE copy today!
“That’s correct! Congratulations, you’re our new Biotech Jeopardy Champion!”

That’s pretty much how Monday night went for Celator, except, few people, if anyone, outside of Celator would have gotten the right answer. The company is tiny, almost unknown and its leukemia drug, Vyxeos, wasn’t expected to demonstrate a significant survival benefit in a phase III study.

But Vyxeos did just that, and as a result, Celator’s stock price nearly quintupled in value.

Based on the positive study results, Celator expects to seek regulatory approval for Vyxeos in the U.S. and Europe later this year.

Vyxeos is an optimized reformulation of the cytarabine/daunorubicin chemotherapy cocktail (known colloquially as 7+3 after its dosing regimen) used for decades as the standard of care in elderly patients with acute myeloid leukemia (AML), a cancer of the bone marrow which primarily affects older people.

Based on early clinical work, Celator believed Vyxeos was superior to the old cytarabine/daunorubicin, or 7+3, combination, so the company designed a straightforward phase III study to prove it. More than 300 elderly patients with secondary (high risk) AML were randomized equally to treatment with Vyxeos or the 7+3 regimen. The primary endpoint of the study was overall survival.

Celator was proven right. Treatment with Vyxeos reduced the risk of death by 31% compared to 7+3. The survival benefit favoring Vyxeos — 3.6 months at the median — was statistically significant, achieving the primary endpoint of the study.

There were no substantial differences in the rate of adverse events between the two arms of the study, Celator said. Within 60 days of beginning treatment, 14% of Vyxeos patients died compared to 21% of 7+3 patients.

“The overall survival advantage seen with CPX-351 [Vyxeos] compared to 7+3, along with a superior response rate and no increase in serious toxicity indicates that we’ll likely have a new standard of care for treating older patients with secondary AML,” said Dr. Jeffrey E. Lancet, a blood cancer specialist at the Moffitt Cancer Center and the principal investigator for the study, in a statement.

Celator believes it can achieve U.S. and European Vyxeos sales in the range of $200-270 million based on the subset of AML patients enrolled in the phase III study. If use of Vyxeos is expanded into other AML patient populations, peak sales could reach $690-780 million, the company estimates.

To hit those targets, Celator will need to convince insurance companies that a reformulation of two generic drugs justifies a higher, branded price. The significant survival benefit favoring Vyxeos, if it holds up, helps the company’s argument.

Heading into Monday night’s Vyxeos study announcement, Celator’s market cap was under $60 million. [This also means Celator managed to become just the second biotech company to escape the Feuerstein-Ratain Rule.]

After dropping the Vyxeos news, Celator shares jumped 368% to $7.86 per share. At that price, the company’s market cap increased to approximately $275 million.

Celator plans to sell Vyxeos in the U.S. and find a marketing partner to handle sales outside the country. The company had $24 million in cash at the end of the September 2015 quarter, enough to last into the second half of this year, according to the company’s SEC filings. Celator will need more money to market Vyxeos, if the drug is approved, but whether that cash comes via dilutive stock sales or through proceeds from a marketing partnership remains to be seen.

Celator could also be an acquisition target. Japanese drug companies, in particular, have shown interest in the past in acquiring smaller blood-cancer drug companies. In 2014, Daiichi Sankyo bought Ambit BioSciences. In 2013, Otsuka acquired Astex Pharmaceuticals. The largest such deal goes back to 2008 when Takeda purchased Millennium Pharmaceuticals.

Celator developed Vyxeos with financial assistance from the Leukemia & Lymphoma Society (LLS.) If Vyxeos is FDA approved, it would mark the first time LLS’s direct investment in a biotech company resulted in bringing a new drug to the market. As part of its deal with Celator, LLS is entitled to royalties on sales of Vyxeos.

“From the start, LLS recognized the potential of CPX-351 [Vyxeos], so we are very gratified with the results of this clinical trial, and we are hopeful that this positive news brings us a step closer to delivering better outcomes for patients with high-risk (secondary) AML,” said LLS CEO Louis DeGennaro, in a statement.

Celator plans to present more detailed data from the Vyxeos AML study at the American Society of Clinical Oncology annual meeting in June.

Source: The Street